Clinical trials: Antipsychotic
Schizophrenia
Alleviating the Metabolic Side Effects of Antipsychotic Medications
The use of antipsychotic medications has increased over the past decade. While more recently developed medications are improved with regards to extrapyramidal side effects, the use of atypical antipsychotics has been associated…
- Trial name
- NCT01567124
- Testing
- Moxonidine
- Where
- 4 sites in Australia
- Sponsor
- Baker Heart and Diabetes Institute
Schizophrenia
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
- Trial name
- NCT02634346
- Testing
- ALK3831, Olanzapine
- Where
- 31 sites in United States, Bulgaria and 2 more
- Volunteers
- 403 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizophrenia and Disorders With Psychotic Features
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the…
- Conditions
- Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
- Trial name
- NCT02307396
- Testing
- Olanzapine, Amisulpride, Risperidone
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Technical University of Munich
Metabolic Disturbance, Hyperprolactinemia
Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are: 1.
- Conditions
- Metabolic Disturbance, Hyperprolactinemia, Schizophrenia
- Trial name
- NCT06326840
- Testing
- Metformin
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Taipei Medical University Hospital
Schizophrenia, Bipolar Disorder
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
The purpose of this study is to investigate the efficacy and safety of long-term psychopharmacotherapy in schizophrenia or bipolar disorder in terms of psychopathology and side effects.
- Trial name
- NCT00330226
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Hospital
Healthy Controls
Intranasal Insulin and Olanzapine Study in Healthy Volunteers
Antipsychotic (AP) medications are considered to be the gold standard treatment for psychotic disorders including schizophrenia.
- Trial name
- INI/OLA (NCT03741478)
- Testing
- OLANZapine 2.5 MG, Insulin Lispro 100 UNT/ML, Saline
- Where
- 2 sites in Canada
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
Clozapine has been demonstrated to be clinically superior to other antipsychotics in treatment-resistant schizophrenia (TRS), and is positioned as such in treatment guidelines.
- Trial name
- NCT02640300
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Metabolic Syndrome X
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
- Trial name
- MESSAGE (NCT00448630)
- Testing
- No intervention
- Where
- 47 sites in Turkey (Türkiye)
- Volunteers
- 328 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients
- Trial name
- NCT04076371
- Testing
- olanzapine-sertraline combination, only olanzapine, risperidone-sertraline combination
- Volunteers
- 1,640 people
- Sponsor
- Beijing HuiLongGuan Hospital
Metabolic Syndrome, Schizophrenia
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole…
- Trial name
- NCT00508157
- Testing
- Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- Where
- 30 sites in Belgium, Czechia and 7 more
- Volunteers
- 125 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Safety and Efficacy of Switching to Quetiapine in Outpatients With Schizophrenia
This is a single-arm, phase IV, open-label, prospective, non interventional study in approximately 600 patients that will be followed for 6 months in order to evaluate the safety and efficacy of quetiapine.
- Trial name
- Q-chase (NCT00690365)
- Volunteers
- 576 people
- Sponsor
- AstraZeneca
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with…
- Trial name
- SWITCH (NCT04312503)
- Testing
- Lurasidone, aripiprazole, olanzapine, quetiapine or risperidone
- Where
- 18 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Psychosis
A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months…
- Trial name
- NCT06546475
- Testing
- N-Acetylcysteine
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia
The primary objectives of this study are to evaluate the efficacy and safety of 3 fixed doses of paliperidone palmitate administered i.m. after an initial loading dose of 150 mg eq.
- Trial name
- NCT00590577
- Testing
- Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Paliperidone palmitate 100 mg eq.
- Where
- 66 sites in United States, Malaysia and 6 more
- Volunteers
- 652 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Schizoaffective Disorder
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months.
- Trial name
- NCT00373672
- Testing
- armodafinil (Nuvigil)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Northwestern University
Child Mental Disorders, Obesity
Healthy Bodies, Healthy Kids
The US prevalence of childhood-onset obesity and type 2 diabetes, both predictors of cardiovascular risk, have increased to epidemic proportions in recent decades.
- Conditions
- Child Mental Disorders, Obesity, Metabolic Syndrome
- Trial name
- NCT01222494
- Testing
- Behavioral Weight Loss, Diet and Exercise Education
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
To detect the effect of second-generation antipsychotic drug on the neural activity.
- Trial name
- NCT01931059
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health